Radiopharm Theranostics, Ltd

This early-stage study is testing a new radioactive drug called 161Tb-RAD402 in men with advanced prostate cancer that has stopped responding to standard hormone-blocking treatments. The drug is designed to seek out and deliver radiation directly to prostate cancer cells. The mai…

This is a very early study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD202 for people with advanced HER2-positive solid tumors. The study will enroll about 30 adults whose cancer has progressed after standard treatments. First, a small 'im…

This is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…

This early-stage trial is testing a new radioactive drug called 177LuBetaBart in adults with advanced solid cancers that have stopped responding to standard treatments. The study aims to find a safe dose and see if the drug shows early signs of fighting tumors. Participants will …

This study is testing a new imaging agent called RAD101 for PET scans. The goal is to see if it can better identify when brain tumors from common cancers like lung or breast cancer have returned after previous radiation treatment. About 30 adults who are suspected of having recur…

This early-stage study aims to understand the safety and radiation exposure of an experimental imaging agent called RAD301. It will involve 9 participants, including both healthy volunteers and people with certain solid tumors like pancreatic or lung cancer. Participants will rec…